Preparation and Characterization of Ion-Sensitive Brimonidine Tartrate In Situ Gel for Ocular Delivery [PDF]
Pharmaceuticals, 2023 Brimonidine tartrate (BRT) is a highly selective α2 adrenergic receptor agonist as treatment for patients with open angle glaucoma and high intraocular pressure.
Haonan Xu +6 more
doaj +5 more sources
Fabrication of Anti-glaucoma Nanofibers as Controlled-Release Inserts for Ophthalmic Delivery of Brimonidine Tartrate: In Vivo Evaluation in Caprine Eye [PDF]
Advanced Pharmaceutical BulletinPurpose: Chronic ailments usually decrease the quality of life due to the requirement for repetitive administration of drugs. Glaucoma is a chronic eye disease occurred because of increased intraocular pressure (IOP).
Fariba Shaikhi Shoushtari +4 more
doaj +5 more sources
Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study [PDF]
Drug Delivery, 2019 Brimonidine tartrate (BRT) is a hydrophilic α2 adrenergic agonist used for the treatment of glaucoma. Glaucoma is an ocular disease affecting the anterior segment of the eye requiring lifetime treatment.
Alaa Emad Eldeeb +2 more
doaj +5 more sources
The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [PDF]
Clinical Ophthalmology, 2014 Toyoaki Tsumura,1 Keiji Yoshikawa,2 Tairo Kimura,3 Hirotaka Suzumura,4 Miwako Kawashima,5 Mami Nanno,6 Kiyotaka Ishijima,7 Ryuji Takeda8 1Fussa Hospital, Tokyo, Japan; 2Yoshikawa Eye Clinic, Tokyo, Japan; 3Ueno Eye Clinic, Tokyo, Japan; 4Suzumura Eye ...
Tsumura T +7 more
doaj +4 more sources
Severe Central Nervous System and Respiratory Depression in a Neonate Following Accidental Oral Ingestion of Brimonidine Tartrate. [PDF]
CureusBrimonidine is a third-generation alpha-2 adrenergic agonist and is classified as an ocular hypotensive agent. It is used for chronic glaucoma treatment by lowering intraocular pressure, crucial for preventing blindness.
Gul F +5 more
europepmc +4 more sources
Effects of brimonidine tartrate 0.1% ophthalmic solution on the pupil, refraction, and light reflex. [PDF]
Sci Rep, 2018 AbstractThis study aimed to assess changes in pupil size, uncorrected visual acuity, refraction, and the direct and consensual light reflexes after instillation of brimonidine 0.1% in healthy subjects. The investigation comprised 46 eyes of 23 healthy subjects with no eye diseases in whom brimonidine 0.1% was instilled in the right eye.
Kato COS +4 more
europepmc +6 more sources
Does topical brimonidine tartrate help NAION? [PDF]
British Journal of Ophthalmology, 2003 There is no proved treatment for non-arteritic anterior ischaemic optic neuropathy (NAION). Topical brimonidine tartrate has been reported to have a neuroprotective benefit for retinal ganglion cells following experimental elevation of intraocular pressure and optic nerve injury in the rat, which is blocked with coadministration of the α-2 antagonist ...
HE Fazzone
openalex +5 more sources
A validated stability-indicating HPLC method for determination of brimonidine tartrate in BRI/PHEMA drug delivery systems [PDF]
Chemistry Central Journal, 2017 Background A simple, rapid and accurate stability-indicating reverse phase high performance liquid chromatography (RP-HPLC) was developed and validated for the determination of brimonidine tartrate in brimonidine tartrate/poly(2-hydroxyethyl methacrylate)
Jianguo Sun, Xiuwen Zhang, Taomin Huang
doaj +2 more sources
Use of brimonidine tartrate to resolve telangiectatic matting: case report. [PDF]
J Vasc Bras, 2020 Sclerotherapy is currently the treatment of choice for telangiectasias and reticular veins, with grade 1A recommendation in the European Guideline for sclerotherapy. The most common side effects of this procedure are hyperpigmentation and telangiectatic matting, the second of which provokes great concern because of the esthetic damage and the ...
de Mello BAS +5 more
europepmc +3 more sources
Delayed hypersensitivity to brimonidine tartrate 0.2% associated with high intraocular pressure [PDF]
Eye, 2002 To report the late presentation of an allergic reaction to brimonidine tartrate 0.2% associated with an elevation of intraocular pressure.During a 6-month period six Caucasian patients (three were male), with primary open angle glaucoma (POAG) or ocular hypertension, with an allergic reaction to brimonidine tartrate eye drops were identified ...
Patrick Watts, N R Hawksworth
openalex +3 more sources